Stepan H, Jank A
Abteilung für Geburtsmedizin, Universitätsklinikum Leipzig.
Z Geburtshilfe Neonatol. 2009 Jun;213(3):101-5. doi: 10.1055/s-0029-1224142. Epub 2009 Jun 17.
Angiogenic factors like placental growth factor (PlGF) and its anti-angiogenic antagonists soluble fms-like tyrosine kinase 1 (sFlt1) and soluble endoglin (sEng) are closely related to the pathogenesis of preeclampsia and intrauterine growth restriction (IUGR). The discovery and investigation of these angiogenic factors could characterize important pathogenetic mediators of preeclampsia or even the cause for placental dysfunctions. These anti-angiogenic proteins are dramatically elevated in maternal circulation weeks prior to the onset of the syndrome preeclampsia. Since it is known that altered maternal sFlt1, sEng and PlGF levels are detectable weeks prior to the onset of these pregnancy complications, it was the aim of the study to investigate the predictive value of these markers in high-risk second trimester pregnancies characterized by abnormal uterine perfusion. Using both factors, sFlt1 and PlGF, early-onset preeclampsia can be predicted with 83% sensitivity and 95% specificity. Combined analysis of sEng and sFlt1 is able to predict early-onset PE even with a sensitivity of 100% and a specificity of 93.3%. This shows, that the concurrent measurement of uterine perfusion and angiogenic factors allows an efficient prediction of early-onset pregnancy complications, particularly preeclampsia. The next step will be the development of therapeutic tools that have positive impact on the clinical symptoms via the inhibition of sFlt1 and or sEng.
血管生成因子,如胎盘生长因子(PlGF)及其抗血管生成拮抗剂可溶性fms样酪氨酸激酶1(sFlt1)和可溶性内皮糖蛋白(sEng),与子痫前期和胎儿生长受限(IUGR)的发病机制密切相关。这些血管生成因子的发现和研究可能会明确子痫前期重要的发病机制介质,甚至是胎盘功能障碍的原因。在子痫前期综合征发作前数周,这些抗血管生成蛋白在母体循环中显著升高。由于已知在这些妊娠并发症发作前数周就能检测到母体sFlt1、sEng和PlGF水平的改变,本研究的目的是探讨这些标志物在以子宫灌注异常为特征的高危孕中期妊娠中的预测价值。使用sFlt1和PlGF这两个因子,可以预测早发型子痫前期,灵敏度为83%,特异性为95%。sEng和sFlt1的联合分析甚至能够以100%的灵敏度和93.3%的特异性预测早发型子痫前期。这表明,同时测量子宫灌注和血管生成因子能够有效预测早发型妊娠并发症,尤其是子痫前期。下一步将是开发通过抑制sFlt1和/或sEng对临床症状产生积极影响的治疗工具。